ArticlePLoS computational biology2010
Tumor growth rate determines the timing of optimal chronomodulated treatment schedules.
Article in PLoS computational biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Theoretical chronobiology of circadian timing-gold mine or minefield?Npj biological timing and sleep · 2026Review
- Time after time - circadian clocks through the lens of oscillator theory.FEBS letters · 2026Review
- Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy.RSC advances · 2025Review
- Combining lineage correlations and a small molecule inhibitor to detect circadian control of the cell cycle.iScience · 2025Article
- A combined mathematical and experimental approach reveals the drivers of time-of-day drug sensitivity in human cells.Communications biology · 2025Article
- Reproductive state-dependent cell turnover in the inner ear of the plainfin midshipman fish (Porichthys notatus).The Journal of experimental biology · 2025Article
- Time-of-day effects of cancer drugs revealed by high-throughput deep phenotyping.Nature communications · 2024Article
- Hypermetabolic state is associated with circadian rhythm disruption in mouse and human cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Crosstalk between Circadian Rhythm Dysregulation and Tumorigenesis, Tumor Metabolism and Tumor Immune Response.Aging and disease · 2024Review
- Circadian clock and lipid metabolism disorders: a potential therapeutic strategy for cancer.Frontiers in endocrinology · 2023Review
- Circadian rhythms and cancers: the intrinsic links and therapeutic potentials.Journal of hematology & oncology · 2022Review
- Chronotherapy of Early Colon Cancer: Advantage of Morning Dose Schedules.Cancer informatics · 2022Article
- Circadian Rhythms, Disease and Chronotherapy.Journal of biological rhythms · 2021Review
- Roles of circadian clocks in cancer pathogenesis and treatment.Experimental & molecular medicine · 2021Review
- Synergies of Multiple Zeitgebers Tune Entrainment.Frontiers in network physiology · 2021Article
- Optimization of Cancer Treatment in the Frequency Domain.The AAPS journal · 2019Article
- Mathematical modeling of circadian rhythms.Wiley interdisciplinary reviews. Systems biology and medicine · 2019Review
- A drift-diffusion checkpoint model predicts a highly variable and growth-factor-sensitive portion of the cell cycle G1 phase.PloS one · 2018Article
- Systems Chronotherapeutics.Pharmacological reviews · 2017Review
- Protein sequestration versus Hill-type repression in circadian clock models.IET systems biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In host and cancer tissues, drug metabolism and susceptibility to drugs vary in a circadian (24 h) manner. In particular, the efficacy of a cell cycle specific (CCS) cytotoxic agent is affected by the daily modulation of cell cycle activity in the target tissues. Anti-cancer chronotherapy, in which treatments are administered at a particular time each day, aims at exploiting these biological rhythms to reduce toxicity and improve efficacy of the treatment. The circadian status, which is the timing of physiological and behavioral activity relative to daily environmental cues, largely determines the best timing of treatments. However, the influence of variations in tumor kinetics has not been considered in determining appropriate treatment schedules. We used a simple model for cell populations under chronomodulated treatment to identify which biological parameters are important for the successful design of a chronotherapy strategy. We show that the duration of the phase of the cell cycle targeted by the treatment and the cell proliferation rate are crucial in determining the best times to administer CCS drugs. Thus, optimal treatment times depend not only on the circadian status of the patient but also on the cell cycle kinetics of the tumor. Then, we developed a theoretical analysis of treatment outcome (TATO) to relate the circadian status and cell cycle kinetic parameters to the treatment outcomes. We show that the best and the worst CCS drug administration schedules are those with 24 h intervals, implying that 24 h chronomodulated treatments can be ineffective or even harmful if administered at wrong circadian times. We show that for certain tumors, administration times at intervals different from 24 h may reduce these risks without compromising overall efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.